Antihypertensive Efficacy and Safety of Candesartan/HCT 32/25 mg in Comparison With Individual Components and Placebo
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00434967 |
|
Recruitment Status :
Completed
First Posted : February 14, 2007
Results First Posted : June 17, 2009
Last Update Posted : December 16, 2010
|
Sponsor:
AstraZeneca
Information provided by:
AstraZeneca
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Brief Summary:
The aim is to compare the blood pressure lowering effect of the combination of candesartan cilexetil (candesartan) 32 mg and hydrochlorothiazide (HCT) 25 mg to that of candesartan 32 mg alone, HCT 25 mg alone and placebo in hypertensive adults.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Hypertension | Drug: Candesartan cilexetil Drug: Hydrochlorothiazide Drug: Candesartan/HCT 32/25 mg | Phase 3 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 2207 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | A Double-blind, Randomised, 4-arm Parallel Group, Multicentre, 8-week, Phase III Study to Assess the Antihypertensive Efficacy and Safety of the Combination of Candesartan Cilexetil (CC) 32 mg and Hydrochlorothiazide (HCT) 25 mg Compared With CC 32 mg, HCT 25 mg and Placebo in Hypertensive Adults |
| Study Start Date : | January 2007 |
| Actual Primary Completion Date : | January 2008 |
| Actual Study Completion Date : | January 2008 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Hypertension
| Arm | Intervention/treatment |
|---|---|
|
No Intervention: 4
Placebo
|
|
|
Active Comparator: 2
Candesartan cilexetil
|
Drug: Candesartan cilexetil
32 mg oral tablet
Other Name: ATACAND |
|
Active Comparator: 3
Hydrochlorothiazide (HCT)
|
Drug: Hydrochlorothiazide
25 mg oral tablet
Other Name: HCTZ |
|
Experimental: 1
Candesartan cilexetil + Hydrochlorothiazide Combination
|
Drug: Candesartan cilexetil
32 mg oral tablet
Other Name: ATACAND Drug: Hydrochlorothiazide 25 mg oral tablet
Other Name: HCTZ Drug: Candesartan/HCT 32/25 mg |
Primary Outcome Measures :
- Change in Sitting Diastolic Blood Pressure (DBP) From Baseline to the End of the Study (From Baseline to 8 Weeks). [ Time Frame: 8 weeks ]Change (reduction) in sitting DBP at the end of the study, when compared to sitting DBP at baseline.
- Change in Sitting Systolic Blood Pressure (SBP) From Baseline to the End of the Study (Baseline to 8 Weeks) [ Time Frame: 8 weeks ]Change (reduction) in sitting SBP at the end of the study, when compared to sitting SBP at baseline.
Secondary Outcome Measures :
- The Number of Patients With Controlled Sitting DBP and Sitting SBP in Each Treatment Group at the End of the Study [ Time Frame: 8 weeks ]Controlled sitting SBP and sitting DBP are defined as having sitting SBP < 140 mmHg and sitting DBP < 90 mmHg at the end of the study
- Compare Candesartan/HCT 32/25 mg to Its Components and to Placebo With Regard to Hypertension Control Rate at the End of the Study (Patients With Controlled Sitting SBP and Sitting DBP). [ Time Frame: Baseline to 8 weeks ]
- To Describe Safety and Tolerability of the Study Treatments With Regard to Adverse Events Including Those That Lead to Treatment Discontinuation as Well as With Regard to Pulse Rate, Laboratory, Electrocardiographic and Physical Examination Findings. [ Time Frame: Baseline to 8 weeks ]
- To Compare Treatment With Candesartan/HCT 32/25 mg to Each of Its Components With Regard to Change From Baseline to Week 8 in Standing DBP and Standing SBP. [ Time Frame: Baseline to 8 weeks ]
- To Compare Candesartan/HCT 32/25 mg to Its Components and to Placebo With Regard to Sitting DBP Control Rate at the End of the Study (Patients With Controlled Sitting DBP Are Defined as Having a Sitting DBP <90 mmHg at the End of the Study). [ Time Frame: Baseline to 8 weeks ]
- To Compare Candesartan/HCT 32/25 mg to Its Components and to Placebo With Regard to Sitting DBP Responder Rate (Decrease in Sitting DBP ≥10 mmHg From Baseline to the End of the Study or a Sitting DBP <90 mmHg at the End of the Study). [ Time Frame: Baseline to 8 weeks ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 20 Years to 80 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Patients will be eligible for enrolment into the study (Visit 1) if they fulfil all of the following criteria:
- Provision of signed Informed Consent
- Primary hypertension, untreated or treated with a maximum of 2 antihypertensive drugs (substances), which the patient and the physician are willing to withdraw at enrolment and replace with placebo.
- Mean sitting DBP 90-114 mmHg (value calculated in the eCRF) at Visits 1 and 2
- Patients will be eligible for randomisation (Visit 4) if they fulfil the following criterion:
- Mean sitting DBP of 90-114 mmHg (value calculated in the eCRF) at the end of the 4-week single-blind placebo run-in period. The run-in period should not be shorter than 4 weeks.
Exclusion Criteria:
- Pregnant or lactating women, or women of childbearing potential not practising an adequate method of contraception eg, intrauterine device, oral contraception or progesterone implant. Pregnancy must be excluded by a negative pregnancy test at Visit 1.
- Secondary or malignant hypertension
- Sitting SBP of 180 mmHg or more
- Myocardial infarction, stroke, coronary bypass surgery or transient ischaemic attack within 6 months before enrolment
- Angina pectoris requiring more treatment than short-acting nitrates
- Chronic use of NSAIDs
- Aortic or mitral valve stenosis
- Cardiac failure requiring treatment
- Cardiac arrhythmia requiring treatment
- Gout
- Renal artery stenosis or kidney transplantation
- Intravascular volume depletion
- Hypersensitivity to any component of the investigational products or to any sulphonamide derived drugs
- Concomitant disease which may interfere with the assessment of the patient
- Past or present alcohol or drug abuse, or any condition associated with poor compliance that in the opinion of the investigator might affect the patient's participation in the study
- Chronic liver disease
- Concomitant or previous treatment with any other investigational drug within 20 days of enrolment
- Previous enrolment in the present study
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00434967
Locations
| Belgium | |
| Research Site | |
| Dour, Belgium | |
| Research Site | |
| Gozée, Belgium | |
| Research Site | |
| Hasselt, Belgium | |
| Research Site | |
| Linkebeek, Belgium | |
| Research Site | |
| Marchovelette, Belgium | |
| Research Site | |
| Ronquières, Belgium | |
| Research Site | |
| Saint-Médard, Belgium | |
| Research Site | |
| Steenokkerzel, Belgium | |
| Latvia | |
| Research Site | |
| Daugavpils, Latvia | |
| Research Site | |
| Ogre, Latvia | |
| Research Site | |
| Riga, Latvia | |
| Malta | |
| Research Site | |
| Gozo, Malta | |
| Research Site | |
| Gwardiamangia, Malta | |
| Romania | |
| Research Site | |
| Arad, Romania | |
| Research Site | |
| Bucuresti, Romania | |
| Research Site | |
| Iasi, Romania | |
| Research Site | |
| Pitesti, Romania | |
| Research Site | |
| Ploiesti, Romania | |
| Research Site | |
| Targoviste, Romania | |
| Research Site | |
| Timisoara, Romania | |
| Russian Federation | |
| Research Site | |
| Moscow, Russian Federation | |
| Research Site | |
| St. Petersburg, Russian Federation | |
| Slovakia | |
| Research Site | |
| Bratislava, Slovakia | |
| Research Site | |
| Levice, Slovakia | |
| Research Site | |
| Lucenec, Slovakia | |
| Research Site | |
| Presov, Slovakia | |
| Research Site | |
| Sahy, Slovakia | |
Sponsors and Collaborators
AstraZeneca
Investigators
| Study Director: | Michael Klibaner, MD | AstraZeneca | |
| Principal Investigator: | Istvan Edes, MD | DEOEC Institute of Cardiology |
| ClinicalTrials.gov Identifier: | NCT00434967 |
| Other Study ID Numbers: |
D2456C00002 EudraCT No. 2006-003963-30 |
| First Posted: | February 14, 2007 Key Record Dates |
| Results First Posted: | June 17, 2009 |
| Last Update Posted: | December 16, 2010 |
| Last Verified: | November 2010 |
Keywords provided by AstraZeneca:
|
Blood pressure reduction combination therapy candesartan cilexetil hydrochlorothiazide |
Additional relevant MeSH terms:
|
Hypertension Vascular Diseases Cardiovascular Diseases Hydrochlorothiazide Candesartan Candesartan cilexetil Antihypertensive Agents Diuretics |
Natriuretic Agents Physiological Effects of Drugs Sodium Chloride Symporter Inhibitors Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Angiotensin II Type 1 Receptor Blockers Angiotensin Receptor Antagonists |